D46.B
Refractory cytopenia with multilineage dysplasia and ring sideroblasts
Clinical Classification Guidelines
Inclusion Terms
- RCMD RS
Medical Intelligence & Overview
Refractory Cytopenia with Multilineage Dysplasia and Ring Sideroblasts (RCMD RS) is a rare blood disorder classified under ICD-10 code D46.B. It is a type of myelodysplastic syndrome (MDS), which involves abnormal development of blood cells in the bone marrow. Patients with RCMD RS typically experience a reduction in blood cell counts, leading to a variety of health issues. This condition is characterized by dysplastic (abnormally formed) blood cells across multiple lineages, along with the presence of ring sideroblasts—abnormal iron-laden red blood cell precursors. Understanding RCMD RS can help patients grasp the nature of their condition, guiding them in conversations with healthcare providers and making informed decisions about their health care management.
Causes & Symptoms
Clinical Causes: Genetic mutations that affect blood cell development Environmental exposures such as radiation or certain chemicals Previous chemotherapy or other treatments for cancer Age-related changes in the bone marrow
Key Symptoms: Fatigue and weakness Easy bruising or bleeding Unintentional weight loss Shortness of breath Frequent infections Pale skin due to anemia Petechiae or small red spots on the skin
Diagnostic & Treatment
Diagnosis Path: Diagnosis of RCMD RS involves a combination of blood tests and bone marrow examination. Blood tests often reveal cytopenias, which include low levels of red blood cells, white blood cells, and platelets. A bone marrow biopsy provides detailed information about cell morphology, showing multilineage dysplasia and the presence of ring sideroblasts. Additional tests, such as genetic analysis, may help identify specific mutations associated with the condition. The diagnosis must be differentiated from other myelodysplastic syndromes and marrow disorders to establish an accurate understanding of the disorder.
Treatment Protocols: Treatment strategies for RCMD RS aim to manage symptoms, reduce complications, and improve quality of life. Approaches may include: - Supportive care such as transfusions of red blood cells or platelets - Use of growth factors to stimulate blood cell production - Disease-modifying agents like hypomethylating agents - Antibiotics or antifungal medications to prevent or treat infections - Consideration of stem cell transplantation in suitable cases While there is no cure for all cases, ongoing monitoring and tailored treatment plans can help manage the condition. Patients should work closely with their healthcare team to determine the best approach based on their overall health and disease progression.
Clinical Advice & FAQs
Billing Guidance
Is D46.B a billable ICD-10 code?
Yes, D46.B is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D46.B?
Clinical documentation must specify the nature of Refractory cytopenia with multilineage dysplasia and ring sideroblasts and any associated comorbidities for accurate reporting.
Cite this Clinical Reference